Sign In
Buy ABEO
$6.42
-0.0500 (-0.773%)
At Close: Jul 31, 2026
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
08:30am, Thursday, 02'nd Apr 2026
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as th
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
01:10am, Wednesday, 25'th Mar 2026
Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
01:18pm, Thursday, 19'th Mar 2026
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB,
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
03:12pm, Tuesday, 17'th Mar 2026
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
07:30am, Tuesday, 17'th Mar 2026
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
07:30am, Monday, 09'th Mar 2026
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene z
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth qu
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of “Moderate Buy” from Analysts
02:09am, Wednesday, 18'th Feb 2026
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, Marketbeat repor
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:04am, Monday, 09'th Feb 2026
CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar
Madhav Vasanthavada Sells 12,610 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock
05:32am, Wednesday, 28'th Jan 2026
Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) insider Madhav Vasanthavada sold 12,610 shares of the firm's stock in a transaction dated Thursday, January 22nd. The shares were sold at an a
Vishwas Seshadri Sells 69,832 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock
05:23am, Saturday, 24'th Jan 2026
Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) CEO Vishwas Seshadri sold 69,832 shares of the firm's stock in a transaction dated Thursday, January 22nd. The stock was sold at an average pr
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Wednesday, 31'st Dec 2025
CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. T
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of “Moderate Buy” by Brokerages
03:18am, Tuesday, 30'th Dec 2025
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the stock, MarketBeat reports.
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
07:30am, Monday, 15'th Dec 2025
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer
AWM Investment Company Inc. Acquires New Shares in Abeona Therapeutics Inc. $ABEO
03:50am, Saturday, 13'th Dec 2025
AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ: ABEO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm b
